Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,785 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction.
Yamazaki H, Iwasaki H, Yamashita T, Yoshida T, Suganuma N, Yamanaka T, Masudo K, Nakayama H, Kohagura K, Rino Y, Masuda M. Yamazaki H, et al. Among authors: yamashita t. In Vivo. 2017 Nov-Dec;31(6):1225-1228. doi: 10.21873/invivo.11195. In Vivo. 2017. PMID: 29102951 Free PMC article.
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Sagara Y, et al. Among authors: yamashita t. Breast Cancer Res Treat. 2018 Oct;171(3):675-683. doi: 10.1007/s10549-018-4873-0. Epub 2018 Jul 3. Breast Cancer Res Treat. 2018. PMID: 29971625 Clinical Trial.
Nephrectomy for Metastatic Kidney Tumor in Patients with Differentiated Thyroid Cancer: A Report of Two Cases.
Yamazaki H, Kishida T, Noguchi G, Iwasaki H, Suganuma N, Masudo K, Nakayama H, Yamashita T, Yamanaka T, Sugawara Y, Matsubara Y, Kohagura K, Rino Y, Masuda M. Yamazaki H, et al. Among authors: yamashita t. Case Rep Endocrinol. 2018 Nov 11;2018:7842792. doi: 10.1155/2018/7842792. eCollection 2018. Case Rep Endocrinol. 2018. PMID: 30534449 Free PMC article.
Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.
Niikura N, Nakatukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y. Niikura N, et al. Among authors: yamashita t. Oncologist. 2020 Feb;25(2):e223-e230. doi: 10.1634/theoncologist.2019-0382. Epub 2019 Oct 8. Oncologist. 2020. PMID: 32043762 Free PMC article. Clinical Trial.
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
Nakatsukasa K, Niikura N, Kashiwabara K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Yamashita T, Umeda M, Mukai H, Ota Y. Nakatsukasa K, et al. Among authors: yamashita t. BMC Cancer. 2021 Jan 7;21(1):34. doi: 10.1186/s12885-020-07746-9. BMC Cancer. 2021. PMID: 33413212 Free PMC article. Clinical Trial.
6,785 results